EAST HANOVER, N.J., Aug. 20, 2020 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for ...
Novartis’ first TV ad for Kesimpta offers the prospect of less drama—less relapsing multiple sclerosis drama, that is. During the commercial, phrases representing that drama such as “unpredictable ...
Please provide your email address to receive an email when new articles are posted on . 80% of study participants remained free of disability-worsening events at 6 months. Cumulative event rates for 6 ...
People with relapsing-remitting and active secondary-progressive multiple sclerosis (MS), as well as those with clinically isolated syndrome (CIS, an initial neurological episode), have a new ...
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of ...
A new monoclonal antibody treatment called Kesimpta (ofatumumab) appears to improve on an older drug in pushing multiple sclerosis (MS) into remission, a new trial shows. Funded by Kesimpta's maker, ...
Novartis AG (NYSE:NVS) released new data Wednesday from the ALITHIOS open-label extension study. Data show first-line Kesimpta (ofatumumab) treatment for up to six years led to less disability and ...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
Roche’s Ocrevus had been growing comfortably as the top choice for new multiple sclerosis patients without major concern over competition until Novartis launched an in-class rival, Kesimpta. Now, ...
Novartis AG NVS announced that the FDA has approved the supplemental biologics license application (sBLA) for its novel B-cell therapy Kesimpta (ofatumumab). The drug is now approved as a subcutaneous ...
A new drug that promises to change the lives of thousands of Australians living with multiple sclerosis has been added to the Pharmaceutical Benefits Scheme. Listing of the drug, known as Kesimpta, is ...
The digital press release with multimedia content can be accessed here: Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback